Medtronic launches ECG belt HF optimization trial

Medtronic (NYSE:MDT) said today it launched a new clinical trial evaluating the use of its ECG belt research system as a diagnostic tool for improving cardiac resynchronization therapy for heart failure patients. The Fridley, Minn.-based company said it has enrolled the first patients in the trial at Des Moines, Iowa’s Mercy Medical Center – West Lakes by principal investigator Dr. Troy Hounshell. “The aim of this technology is to give physicians immediate feedback that may impact clinical decision making at the time of implant and also during follow-up visits. By pairing CRT with the ECG Belt, we have the potential to provide a more personalized and noninvasive approach to help heart failure patients,” Dr. Hounshell said in a press release. The ECG Belt for CRT Response trial aims to enroll 400 patients at 10 US centers to compare patients treated with both the ECG belt diagnostic and CRT against those treated with standard CRT alone, Medtronic said. Trial investigators will use the ECG belt during the trial to analyze the heart electrical activity through real-time synchronization measurements, as well as during CRT implant to help guide placement of the left ventricular lead, Medtronic said. “Our goal for this study is to give clinicians real-time insights to address each patient’s needs, and to help optimize CRT for heart failure patients,” CRT biz GM Dr. Kweli Thompson said in a prepared statement. Last week, Medtronic said ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiac Assist Devices Cardiovascular Clinical Trials Medtronic Source Type: news

Related Links:

AbstractPurpose of reviewDevice-based therapy utilizing cardiac contractility modulation (CCM ™) was approved by the FDA in March 2019 for patients with moderately to severely symptomatic heart failure with reduced ejection fraction between 25 and 45% on optimal guideline-directed medical therapy in normal sinus rhythm and not a candidate for cardiac resynchronization therapy. This review explores the mechanism of action behind CCM, the most recent clinical trials, and the expansion of therapy to additional patient populations.Recent findingsThe most recent trial on CCM explored a two-lead system, which was as equall...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
Conclusions: IAB is associated with new-onset AF and death in CRT recipients and may be helpful in the risk stratification in the context of heart failure management. Abnormal PTFV1 did not demonstrate any prognostic value.Cardiology
Source: Cardiology - Category: Cardiology Source Type: research
Conditions:   Hypotension;   Heart Failure Interventions:   Drug: Dapagliflozin;   Drug: Sacubitril-Valsartan;   Drug: Beta blocker;   Drug: Mineralocorticoid Receptor Antagonist;   Device: Cardiac resynchronization therapy and/or implantable cardioverter defibrillator Sponsor:   Cheng-Hsin General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Moti H Abstract In the present paper we review data of the efficacy of CRT based on baseline QRS duration and morphology in patients with heart failure due to left ventricle systolic dysfunction. We specifically review data that analyzed men and women separately. The main findings suggest benefit of CRT in patients with baseline LBBB, but not in patients without LBBB. Benefit is directly related to QRS duration at baseline with increasing rates and magnitude of echocardiographic response ( in terms of improvement in ejection fraction and decrease un LV size) and clinical response with increasing baseline Q...
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research
Introduction: Danon disease is a rare X-linked dominant genetic disorder caused by defects in the lysosome-associated membrane protein 2 (LAMP2) gene. Unless treated, cardiogenic death is the main cause of mortality. This case report describes a 19-year-old man who was diagnosed with Danon disease and survived for 3 years from symptom onset to death. The mutation in his LAMP2 gene (p.Gly221Ilefs∗19) had not been previously reported. Patient concerns: A 19-year-old man patient was hospitalized for intermittent palpitations. He had no family history of cardiomyopathy, arrhythmia, or sudden cardiac death, but his ...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Cardiac pacemakers where the earliest cardiac implantable electronic devices (CIED) to be used ever since the first implant in 1958. Single chamber pacemaker: Picture below shows a single chamber pacemaker with pulse generator and lead. Two electrodes for stimulation – a proximal ring electrode and distal tip electrode are seen towards the apex of the right ventricle. The pulse generator is seen in the right pectoral region. The lead is coursing through the right subclavian vein into the superior vena cava. From superior vena cava it reaches the right ventricle through the right atrium. A Starr-Edwards prosthetic ao...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: HBC Source Type: blogs
AbstractPurpose of ReviewThe aim of this review is to summarily explain what LV synchrony, coordination, myocardial work, and flow dynamics are, trying to clarify their advantages and limitations in the treatment of heart failure patients undergoing or with implanted cardiac resynchronization therapy (CRT).Recent FindingsCRT is an established treatment for patients with heart failure and left ventricular systolic dysfunction. In the current guidelines, CRT implant indications rely only on electrical dyssynchrony, but in the last years, many aspects of cardiac mechanics (including contractile synchrony, coordination, propag...
Source: Current Heart Failure Reports - Category: Cardiology Source Type: research
AbstractHeart failure is the cardiovascular epidemic of the twenty-first century, with poor prognosis and quality of life despite optimized medical treatment. Despite over the last decade significant improvements, with a major impact on morbidity and mortality, have been made in therapy for heart failure with reduced ejection fraction, little progress was made in the development of devices, with the implantable defibrillator indicated for patients with left ventricle ejection fraction ≤ 35% and cardiac resynchronization therapy for those with QRS ≥ 130 ms and evidence of left bundle branch block...
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
Authors: Majos-Karwacka E, Kraska A, Kowalik I, Smolis-Bak E, Lipiec P, Kasprzak J, Szwed H, Dabrowski R Abstract BACKGROUND: The right ventricle (RV) function is crucial in heart failure with reduced ejection fraction (HFrEF), especially in patients with atrial fibrillation (AF). Aims. To assess the RV structure and function in patients with HFrEF, permanent atrial fibrillation (AF), cardiac resynchronization therapy (CRT) and RV pacing (RVp) with two- and three-dimensional echocardiography. Methods. Patients with ischemic HFrEF (NYHA II-III; LVEF ≤40%) were enrolled. The studied groups were: sinus rhythm (SR, ...
Source: Scandinavian Cardiovascular Journal - Category: Cardiology Tags: Scand Cardiovasc J Source Type: research
Hypothyroidism is known to be associated with adverse clinical outcomes in heart failure. The association between hypothyroidism and cardiac resynchronization therapy outcomes in patients with severe heart fai...
Source: BMC Cardiovascular Disorders - Category: Cardiology Authors: Tags: Research article Source Type: research
More News: Cardiac Resynchronization Therapy | Cardiology | Cardiovascular | Clinical Trials | Heart | Heart Failure | Study